Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non–small-Cell Lung Cancer Patients

Chen, Minjiang; Xu, Yan; Zhao, Jing; Liu, Xiaoyan; Liu, Xiangning; Zhang, Dongming; Shi, Yuequan; Zhang, Li; Zhong, Wei; Wang, Mengzhao

doi:10.1016/j.cllc.2022.12.003

Cited by 7 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 56 studies were deemed eligible for full‐text review. Eventually, 17 studies were in accordance with our inclusion criteria (Figure 1), including eight RCTs, 23–25,31–37 eight retrospective studies, 38–45 and one Non‐RCT 46 . Among them, the randomized controlled clinical trial IMpower150 data came from two literatures, the PFS data came from the literature with Martin Reck as the first author, and the OS data came from the literature with Naoyuki Nogami as the first author.…”

Section: Resultsmentioning

confidence: 99%

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis

Wang

Zhou

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundNon‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR)‐mutated who progressed on EGFR tyrosine‐kinase inhibitor (EGFR‐TKI) therapy have limited therapeutic options. There is still no consensus on the role of immune checkpoint inhibitors (ICIs) in NSCLC with EGFR mutations.MethodsWe did a network meta‐analysis (NMA) with a systematic literature search on PubMed, Embase, Web of Science, and The Cochrane Library. We included all phase II and III randomized controlled trials (RCTs), non‐randomized controlled trials (Non‐RCTs), and retrospective studies. Progression‐free survival (PFS) and overall survival (OS) were assessed through hazard ratios (HR). Objective response rate (ORR) and adverse events (AEs) were assessed through odds ratio (OR) and relative risk (RR), respectively. R software was used to compare the outcomes of different treatments by Bayesian NMA.FindingsWe identified 1835 published results and 17 studies were included ultimately. A total of 2085 patients were included and accepted the following six treatments: ICIs plus chemotherapy (ICIs+Chemo), chemotherapy (Chemo), ICIs monotherapy (ICIs), ICIs plus chemotherapy and antiangiogenic therapy (ICIs+Chemo+Antiangio), antiangiogenic therapy plus chemotherapy (Antiangio+Chemo), ICIs plus antiangiogenic therapy (ICIs+Antiangio). ICIs+Chemo+Antiangio was associated with longer PFS and OS, as well as higher ORR (surface under the cumulative ranking curve [SUCRA], 96%, 90%, 91%). ICIs conferred the safety profile in terms of any‐grade AEs, grade greater than or equal to 3 AEs and any grade leading to treatment discontinuation occurred AEs (SUCRA, 99%, 68%, 94%).InterpretationICIs+Chemo+Antiangio brings the greatest survival benefit in NSCLC patients with EGFR mutations who progressed on EGFR‐TKI therapy, even for whom with baseline brain metastases. Compared with chemotherapy, ICIs has a low incidence of AEs and a benefit in OS.

show abstract

Section: Resultsmentioning

confidence: 99%

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis

Wang

Zhou

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…However, the efficacy of platinum doublet plus immune checkpoint inhibitors has not been reported. In previous studies, platinum doublet plus pembrolizumab resulted in longer progression-free survival and overall survival and higher overall response rate than pembrolizumab monotherapy or platinum doublet administration in patients with EGFR mutation-positive lung cancer who had failed on EGFR-tyrosine kinase inhibitor therapy [8, 9]. Therefore, we chose carboplatin, pemetrexed, and pembrolizumab to treat cystic lung metastases.…”

Section: Discussionmentioning

confidence: 99%

Successful Chemotherapy for Diffuse Cystic Lung Metastases during Targeted Therapy with Osimertinib in a Patient with Non-Small-Cell Lung Cancer: A Literature Review and a Rare Case Report

Matsukida,

Ogawa,

Tanigaki

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

Introduction: Diffuse lung cysts occur owing to several diseases; however, diffuse cystic lung metastases are very rare in the case of lung cancer. We report a rare case of diffuse cystic lung metastases from lung adenocarcinoma and reviewed previously reported cases of cystic lung metastases for lung cancer and determined their characteristics. Case Presentation: A 78-year-old Japanese woman with advanced lung adenocarcinoma was positive for the epidermal growth factor receptor gene mutation exon 21 L858R and had been treated with osimertinib. She presented with multiple bilaterally positioned thin-walled lung cysts and pneumothorax. Lung cysts were diagnosed as cystic lung metastases from lung cancer, and carboplatin, pemetrexed, and pembrolizumab were subsequently administered. All cysts markedly decreased in size, and some disappeared. Conclusion: Effective treatment methods for cystic lung metastases from lung cancer have not been reported. To our knowledge, this is the first case of cystic lung metastases that were successfully treated with chemotherapy.

show abstract

Pemetrexed and platinum with or without pembrolizumab for advanced non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis

Zhao,

Yang,

2024

Clin Transl Oncol

View full text Add to dashboard Cite

Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non–small-Cell Lung Cancer Patients

Cited by 7 publications

References 35 publications

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis

Successful Chemotherapy for Diffuse Cystic Lung Metastases during Targeted Therapy with Osimertinib in a Patient with Non-Small-Cell Lung Cancer: A Literature Review and a Rare Case Report

Pemetrexed and platinum with or without pembrolizumab for advanced non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis

Contact Info

Product

Resources

About